The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.
This study examines the effects of the medication tolcapone among individuals who regularly drink alcohol. Participants in this study will be randomly assigned to take either tolcapone or a matched placebo for 8 days. There are 3 study visits, including 2 MRI scans, and a debriefing session. This study does not involve alcohol treatment. Interested individuals must be referred for participation by the Charleston Alcohol Research Center Clinical Intake and Assessment Core. For more information, call 792-1222 or email email@example.com.